Deals In Depth: October 2012
In a deal valued at $272 million, AZ got exclusive global rights to Ardelyx’s NHE3 program. Pfizer exercised an option to buy spec pharma NextWave for $255 million up front. Biophama companies raised almost $2 billion in October propelled by public offerings. Early venture rounds dominated device financing, which totaled $193 million.
You may also be interested in...
The decision limits US FDA discretion in determining how to regulate products that seem to meet both drug and device standards.
Argenx partners with Elektrofi and Iontas; China’s Qilu obtains global rights to Peptron’s antibody-drug conjugate and also ends co-development pact with Quantum Genomics.
Taysha gains control of GAN candidate and program; BI licenses COMT inhibitors from Lieber Institute; plus three new gene therapy-driven tie-ups between biopharma and academia.